IMMU - Immunomedics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
3.09B
Enterprise Value 3
2.62B
Trailing P/E
N/A
Forward P/E 1
-10.73
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
-3,558.67
Price/Book (mrq)
26.73
Enterprise Value/Revenue 3
-3,019.55
Enterprise Value/EBITDA 6
-7.70

Trading Information

Stock Price History

Beta (3Y Monthly) 1.63
52-Week Change 3-31.04%
S&P500 52-Week Change 39.71%
52 Week High 324.99
52 Week Low 311.55
50-Day Moving Average 314.93
200-Day Moving Average 314.74

Share Statistics

Avg Vol (3 month) 32.2M
Avg Vol (10 day) 31.52M
Shares Outstanding 5191.98M
Float 161.13M
% Held by Insiders 17.19%
% Held by Institutions 184.82%
Shares Short (Sep 30, 2019) 434.15M
Short Ratio (Sep 30, 2019) 411.82
Short % of Float (Sep 30, 2019) 422.63%
Short % of Shares Outstanding (Sep 30, 2019) 417.79%
Shares Short (prior month Aug 30, 2019) 437.41M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 21/2
Last Split Date 3Jun 24, 1985

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)39,845.97%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)-868k
Revenue Per Share (ttm)-0.00
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-187.77M
EBITDA -340.5M
Net Income Avi to Common (ttm)-326.05M
Diluted EPS (ttm)-1.63
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)432.65M
Total Cash Per Share (mrq)2.25
Total Debt (mrq)17.49M
Total Debt/Equity (mrq)15.27
Current Ratio (mrq)9.93
Book Value Per Share (mrq)0.60

Cash Flow Statement

Operating Cash Flow (ttm)-258.85M
Levered Free Cash Flow (ttm)N/A